Novartis AG (NVS)

NYSE: NVS · IEX Real-Time Price · USD
84.83
+2.97 (3.63%)
At close: Jun 24, 2022 4:00 PM
84.85
+0.02 (0.02%)
After-hours: Jun 24, 2022 7:34 PM EDT
3.63%
Market Cap 189.14B
Revenue (ttm) 53.00B
Net Income (ttm) 24.18B
Shares Out 2.23B
EPS (ttm) 10.73
PE Ratio 7.91
Forward PE 13.11
Dividend $3.33 (3.92%)
Ex-Dividend Date Mar 8, 2022
Volume 1,900,227
Open 83.52
Previous Close 81.86
Day's Range 83.35 - 84.83
52-Week Range 79.09 - 95.17
Beta 0.48
Analysts Buy
Price Target 96.50 (+13.8%)
Earnings Date Jul 19, 2022

About NVS

Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology, dermatology, respiratory, cardiovascular, renal, and metabolism medicine products. The Sandoz segment develops, manufactures, and markets finished dosage form medicines; active ingredients and finished dosage fo... [Read more...]

Industry Pharmaceuticals
IPO Date Nov 18, 1991
Employees 110,000
Stock Exchange NYSE
Ticker Symbol NVS
Full Company Profile

Financial Performance

In 2021, Novartis AG's revenue was $52.88 billion, an increase of 5.97% compared to the previous year's $49.90 billion. Earnings were $24.02 billion, an increase of 197.58%.

Financial Statements

Analyst Forecast

According to 35 analysts, the average rating for NVS stock is "Buy." The 12-month stock price forecast is 96.5, which is an increase of 13.76% from the latest price.

Price Target
$96.5
(13.76% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Novartis receives positive CHMP opinion for Scemblix®, a novel treatment for adult patients with chronic myeloid leuk...

Basel, June 24, 2022 — Novartis today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion and recommended grant...

Novartis' (NVS) Oncology Drugs Get Approval for Label Expansion

Novartis (NVS) obtains regulatory approval for label expansion of Tafinlar + Mekinist and Tabrecta.

Novartis renews commitment to neglected tropical disease and malaria elimination, investing USD 250 million over five...

Basel, June 23, 2022 — Novartis endorses the Kigali Declaration on neglected tropical diseases (NTDs) and announces a five-year financial commitment of USD 250 million to the fight against NTDs and mala...

Novartis Tafinlar + Mekinist receives FDA approval for first tumor-agnostic indication for BRAF V600E solid tumors

Basel, June 23, 2022 — Novartis today announced the US Food and Drug Administration (FDA) granted accelerated approval for Tafinlar® (dabrafenib) + Mekinist® (trametinib) for the treatment of adult and ...

Precision BioSciences (DTIL) Stock Treks Higher on Novartis Deal

DTIL stock is advancing in early trading today after Precision BioScience announced a partnership with Novartis, a leading drug maker. The post Precision BioSciences (DTIL) Stock Treks Higher on Novarti...

Other symbols: DTIL

PerkinElmer and Novartis Collaborate to Address the Unmet Need of Sickle Cell Disease in Sub-Saharan Africa

WALTHAM, Mass.--(BUSINESS WIRE)--PerkinElmer Inc., a global leader committed to innovating for a healthier world, today announced that it is collaborating with Novartis, a leading global medicines compa...

Other symbols: PKI

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors Novartis AG - NVS

New York, New York--(Newsfile Corp. - June 15, 2022) - Pomerantz LLP is investigating claims on behalf of investors of Novartis AG ("Novartis" or the "Company") (NYSE: NVS). Such investors are advised t...

What Could a Recession Mean for Healthcare Stocks?

It depends on which subsector you're talking about.

Other symbols: AZNGSKSNYVXRT

Novartis Scemblix®, with novel mechanism of action, shows superior, long-term efficacy and consistent tolerability in...

Basel, June 7, 2022 — Novartis today announced longer-term follow-up data from the Phase III ASCEMBL trial for patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase (P...

Novartis Tafinlar® (dabrafenib) + Mekinist® (trametinib) demonstrates unprecedented efficacy in pediatric patients wi...

Basel, June 6, 2022 — Novartis today announced Tafinlar® (dabrafenib) + Mekinist® (trametinib) significantly improved efficacy in patients ages 1 to 17 years old with BRAF V600 pediatric low-grade gliom...

3 Great Dividend Stocks to Buy in June

Investors should be able to count on recurring income with these stocks.

Other symbols: ABBVVTRS

NOVARTIS ALERT: Bragar Eagel & Squire, P.C. is Investigating Novartis AG on Behalf of Novartis Stockholders and Encou...

NEW YORK--(BUSINESS WIRE)-- #AG--Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Novartis AG (“Novartis” or the “Company”) (NY...

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Novartis AG (NVS) on Beh...

LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Novartis AG (“Novar...

INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Novartis AG (NVS) on Behalf of Investors

BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces an investigation on behalf of Novartis AG (“Novartis” or the “Company”) (NYSE: NVS) investors concerning the Company's possible v...

The Law Offices of Frank R. Cruz Announces Investigation of Novartis AG (NVS) on Behalf of Investors

LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz announces an investigation of Novartis AG (“Novartis” or the “Company”) (NYSE: NVS) on behalf of investors concerning the Company's possibl...

Novartis (NVS) Wins FDA Nod for Label Expansion of Kymriah

Novartis' (NVS) CAR-T cell therapy Kymriah (tisagenlecleucel) gets an FDA approval for a third indication.

FDA approves Novartis Kymriah® CAR-T cell therapy for adult patients with relapsed or refractory follicular lymphoma

Basel, May 28, 2022 — Novartis today announced the US Food and Drug Administration (FDA) has granted accelerated approval for Kymriah® (tisagenlecleucel) for the treatment of adult patients with relapse...

6 Dividend Stocks With High Yields and Low P/E Ratios

6 Dividend stocks with high yields and low P/E ratios. These 6 dividend stocks have yields greater than 2.5% and P/E ratios lower than 16x with a positive earnings growth forecast for 2023.

Other symbols: GSJPMRYUPSVZ

Novartis (NVS) Cosentyx Gets Positive CHMP Opinion for JIA

Novartis (NVS) Cosentyx gets a positive CHMP recommendation for the indication of juvenile idiopathic arthritis.

Novartis Cosentyx® (secukinumab) receives positive CHMP opinion for expanded use in childhood arthritic conditions

Basel, May 20, 2022 — Novartis today announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion for Cosentyx® (secukinumab)...

Three Stock Lunch: JPMorgan, Verizon and Novartis

David Wagner, Aptus Capital Advisors portfolio manager, joins 'Power Lunch' to discuss Wagner's take on stocks like JPMorgan, Verizon and Novartis.

Other symbols: VZJPM

Should You Buy This High-Yielding Big Pharma Stock?

Novartis can provide investors with a market-crushing 3.8% dividend yield -- and that isn't all the stock has to offer.

3 Undervalued Stocks to Buy Before You Sell in May and Go Away

If you really decide to sell in May and go away, you may miss out some profits from these undervalued stocks to buy. The post 3 Undervalued Stocks to Buy Before You Sell in May and Go Away appeared firs...

Other symbols: GST

2 Dividend Stocks to Boost Your Passive Income

Despite challenging economic conditions, these companies are unlikely to cut their dividends.

Other symbols: AAPL

Novartis data at ASCO and EHA showcase latest oncology research and innovation, including in breast and prostate cancer

Basel, May 12, 2022 — Novartis highlights data from across its oncology portfolio at the upcoming 2022 American Society of Clinical Oncology (ASCO) Annual Meeting and the European Hematology Association...